Neuropsychological characteristics of benign multiple sclerosis patients: A two-year matched cohort study

被引:3
|
作者
Hegedus, Katalin [1 ]
Karpati, Judit [1 ]
Iljicsov, Anna [1 ]
Simo, Magdolna [1 ]
机构
[1] Semmelweis Univ, Dept Neurol, Balassa J U 6, H-1083 Budapest, Hungary
关键词
Multiple sclerosis; Benign; Cognitive impairment; Disease modifying treatment; Depression; STOP FOOLING OURSELVES; COGNITIVE IMPAIRMENT; DEPRESSION; SYMPTOMS; ANXIETY; RARE; MS;
D O I
10.1016/j.msard.2019.07.022
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The definition of benign multiple sclerosis (BMS) is still debated. It is mainly based on physical status, however, there is an attempt to involve cognitive functioning or paraclinical factors in order to avoid unnecessary long-term treatment with disease-modifying therapies and to identify these subjects in the early stages of the disease. Therefore the aim of our two-year follow-up study was to investigate the pattern of cognitive functioning and depression in patients with BMS compared to treated relapsing-remitting MS (RRMS) patients and healthy controls. Methods: A group of 22 BMS patients was tested against matched RRMS patients and healthy controls. All individuals underwent neuropsychological evaluation exploring mood and the cognitive domains most frequently impaired in MS. MS patients were retested at two-year follow-up. Results: In terms of cognitive functions there were no differences between BMS and RRMS patients either at baseline or at two-year follow-up. Compared to healthy controls BMS patients showed poorer performance in long-term visuo-spatial memory and information processing speed, whereas, complex attention, working memory, long-term verbal memory - despite slower verbal learning - and executive function were found to be intact. RRMS patients showed significant difference in complex attention, long-term visual memory and information processing speed. Cognitive impairment differed in the patient groups in terms of severity. Both patient groups were depressed compared to controls, but significant differences were found only between BMS and healthy individuals. Conclusion: The results of our study confirm that cognitive functions and mood can be affected in MS independent of disease course and disease modifying treatment. The "benign" label should be treated as only a reference to physical status and non-motor symptoms should be routinely monitored. Without receiving therapy it is an existing entity with longstanding minimal disability.
引用
收藏
页码:150 / 155
页数:6
相关论文
共 50 条
  • [41] Safety of the live attenuated vaccines in patients with multiple sclerosis: a matched-control cohort study
    Carvajal, Rene
    Carbonell, Pere
    Tur, Carmen
    Martinez-Gomez, Xavier
    Esperalba, Juliana
    Rodriguez-Barranco, Marta
    Sao-Aviles, Augusto
    Cobo Calvo, Alvaro
    Borras-Bermejo, Blanca
    Guio-Sanchez, Claudia
    Cardenas-Robledo, Simon
    Rodrigo-Pendas, Jose Angel
    Rio, Jordi
    Castillo-Justribo, Joaquin
    Pappolla, Agustin
    Braga, Nathane
    Mongay-Ochoa, Neus
    Tagliani, Paula
    Arrambide, Georgina
    Rodriguez, Breogan
    Zabalza, Ana
    Midaglia, Luciana
    Vilaseca, Andreu
    Arino, Helena
    Galan, Ingrid
    Comabella, Manuel
    Sastre-Garriga, Jaume
    Montalban, Xavier
    Tintore, Mar
    Otero-Romero, Susana
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 619 - 621
  • [42] Osteoporosis management and secondary fragility fracture rates in patients with multiple sclerosis: a matched cohort study
    Bailey J. Ross
    Austin J. Ross
    Olivia C. Lee
    Timothy L. Waters
    McCayn M. Familia
    William F. Sherman
    Osteoporosis International, 2022, 33 : 1999 - 2010
  • [43] Osteoporosis management and secondary fragility fracture rates in patients with multiple sclerosis: a matched cohort study
    Ross, Bailey J.
    Ross, Austin J.
    Lee, Olivia C.
    Waters, Timothy L.
    Familia, McCayn M.
    Sherman, William F.
    OSTEOPOROSIS INTERNATIONAL, 2022, 33 (09) : 1999 - 2010
  • [44] Variations in and predictors of the occurrence of depressive symptoms and mood symptoms in multiple sclerosis: a longitudinal two-year study
    Sverker Johansson
    Kristina Gottberg
    Marie Kierkegaard
    Charlotte Ytterberg
    BMC Neurology, 16
  • [45] Variations in and predictors of the occurrence of depressive symptoms and mood symptoms in multiple sclerosis: a longitudinal two-year study
    Johansson, Sverker
    Gottberg, Kristina
    Kierkegaard, Marie
    Ytterberg, Charlotte
    BMC NEUROLOGY, 2016, 16
  • [46] Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
    Kappos, Ludwig
    Arnold, Douglas L.
    Bar-Or, Amit
    Camm, A. John
    Derfuss, Tobias
    Sprenger, Till
    Davies, Martin
    Piotrowska, Alexandra
    Ni, Pingping
    Harada, Tomohiko
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (12) : 1605 - 1616
  • [47] Use of health services in people with multiple sclerosis with and without depressive symptoms: a two-year prospective study
    Ytterberg, Charlotte
    Lundqvist, Sanna
    Johansson, Sverker
    BMC HEALTH SERVICES RESEARCH, 2013, 13
  • [48] Use of health services in people with multiple sclerosis with and without depressive symptoms: a two-year prospective study
    Charlotte Ytterberg
    Sanna Lundqvist
    Sverker Johansson
    BMC Health Services Research, 13
  • [49] Clinical course of multiple sclerosis with comorbid endometriosis: A matched cohort study
    Balshi, Alexandra
    Manning, Nova
    Dempsey, John
    Jun, Claire
    Baber, Ursela
    Sloane, Jacob A.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 82
  • [50] Neuropathological characteristics of benign multiple sclerosis
    Stadelmann, C
    MULTIPLE SCLEROSIS, 2005, 11 : S7 - S7